<DOC>
	<DOC>NCT02966756</DOC>
	<brief_summary>This is a Phase 2, open-label, single-arm, multicenter study, evaluating the efficacy of venetoclax in participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) in the presence of 17p deletion.</brief_summary>
	<brief_title>A Study Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<criteria>Participant must have a diagnosis of relapsed or refractory chronic lymphocytic leukemia (CLL) that meets 2008 Modified International Workshop for Chronic Lymphocytic Leukemia (IWCLL) NCIWG Guidelines and the following: Participant must have an indication for treatment according to the 2008 Modified IWCLL National Cancer InstituteWorking Group (NCIWG) Guidelines; Participant must have measurable disease (Blymphocytosis greater than 5 Ã— 10^9/L or an enlarged lymph node(s) (LDi &gt; 1.5 cm at baseline) or hepatomegaly or splenomegaly due to CLL); Participant must have relapsed or refractory CLL after receiving at least one prior line of therapy Relapsed must have completed at least 2 cycles of one prior line of therapy; Refractory must have progressed after at least 1 cycle of one prior line of therapy; Participant must have 17p deletion, assessed by a central laboratory (in bone marrow or peripheral blood). Participant must have an Eastern Cooperative Oncology Group (ECOG) performance score of less than or equal to 2. Participant must have adequate bone marrow function, coagulation profile, renal, and hepatic function, per laboratory reference range at Screening Participant has undergone an allogeneic stem cell transplant. Participant has developed Richter's transformation confirmed by biopsy. Participant has prolymphocytic leukemia. Participant has active and uncontrolled autoimmune cytopenias (for 2 weeks prior to screening), including autoimmune hemolytic anemia (AIHA) and idiopathic thrombocytopenic purpura (ITP). Participant has previously received venetoclax. Participant is known to be positive for Human Immunodeficiency Virus (HIV). Participant has received a biologic agent for antineoplastic intent within 30 days prior to the first dose of study drug. Participant has received any of the following within 14 days or 5 halflives (whichever is shorter) prior to the first dose of study drug, or has not recovered to less than Common Toxicity Criteria (CTC) grade 2 clinically significant adverse effect(s)/toxicity(s) of the previous therapy: Any anticancer therapy including chemotherapy, or radiotherapy; Investigational therapy, including targeted small molecule agents. Participant has known allergy to both xanthine oxidase inhibitors and rasburicase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Relapsed chronic lymphocytic leukemia (CLL)</keyword>
	<keyword>Leukemia</keyword>
	<keyword>17p deletion</keyword>
	<keyword>Refractory chronic lymphocytic leukemia (CLL)</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>venetoclax</keyword>
</DOC>